A detailed history of Blue Fin Capital, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Blue Fin Capital, Inc. holds 14,403 shares of ABBV stock, worth $2.39 Million. This represents 0.59% of its overall portfolio holdings.

Number of Shares
14,403
Previous 14,465 0.43%
Holding current value
$2.39 Million
Previous $2.24 Million 17.0%
% of portfolio
0.59%
Previous 0.58%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$159.82 - $182.1 $9,908 - $11,290
-62 Reduced 0.43%
14,403 $2.62 Million
Q4 2023

Feb 06, 2024

BUY
$137.6 - $154.97 $13,622 - $15,342
99 Added 0.69%
14,465 $2.24 Million
Q3 2023

Oct 19, 2023

BUY
$133.59 - $154.65 $14,828 - $17,166
111 Added 0.78%
14,366 $2.14 Million
Q2 2023

Jul 31, 2023

SELL
$132.51 - $164.9 $1,855 - $2,308
-14 Reduced 0.1%
14,255 $1.92 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $1,735 - $1,998
-12 Reduced 0.08%
14,269 $2.27 Million
Q4 2022

Jan 23, 2023

BUY
$138.31 - $165.87 $5,809 - $6,966
42 Added 0.29%
14,281 $0
Q3 2022

Nov 04, 2022

BUY
$134.21 - $153.93 $109,649 - $125,760
817 Added 6.09%
14,239 $1.91 Million
Q2 2022

Aug 08, 2022

BUY
$137.62 - $174.96 $15,826 - $20,120
115 Added 0.86%
13,422 $2.06 Million
Q1 2022

Apr 12, 2022

BUY
$131.98 - $163.75 $30,223 - $37,498
229 Added 1.75%
13,307 $2.16 Million
Q4 2021

Jan 19, 2022

BUY
$107.43 - $135.93 $52,318 - $66,197
487 Added 3.87%
13,078 $1.77 Million
Q3 2021

Oct 25, 2021

SELL
$106.4 - $120.78 $8,086 - $9,179
-76 Reduced 0.6%
12,591 $1.36 Million
Q2 2021

Jul 19, 2021

SELL
$105.21 - $117.21 $75,014 - $83,570
-713 Reduced 5.33%
12,667 $1.43 Million
Q1 2021

May 05, 2021

SELL
$102.3 - $112.62 $3,785 - $4,166
-37 Reduced 0.28%
13,380 $1.45 Million
Q4 2020

Jan 28, 2021

BUY
$80.49 - $108.67 $30,425 - $41,077
378 Added 2.9%
13,417 $1.44 Million
Q3 2020

Oct 28, 2020

SELL
$85.91 - $100.83 $8,333 - $9,780
-97 Reduced 0.74%
13,039 $1.14 Million
Q2 2020

Aug 10, 2020

SELL
$73.37 - $98.18 $11,152 - $14,923
-152 Reduced 1.14%
13,136 $1.29 Million
Q1 2020

Apr 28, 2020

SELL
$64.5 - $97.79 $41,667 - $63,172
-646 Reduced 4.64%
13,288 $1.01 Million
Q4 2019

Feb 10, 2020

SELL
$72.13 - $90.25 $1,658 - $2,075
-23 Reduced 0.16%
13,934 $1.23 Million
Q3 2019

Nov 07, 2019

SELL
$62.98 - $75.72 $61,405 - $73,827
-975 Reduced 6.53%
13,957 $1.06 Million
Q2 2019

Jul 22, 2019

BUY
$65.7 - $83.98 $5,584 - $7,138
85 Added 0.57%
14,932 $1.09 Million
Q1 2019

Apr 23, 2019

SELL
$77.14 - $90.79 $53,535 - $63,008
-694 Reduced 4.47%
14,847 $1.2 Million
Q4 2018

Jan 16, 2019

SELL
$77.85 - $96.01 $28,960 - $35,715
-372 Reduced 2.34%
15,541 $1.43 Million
Q3 2018

Nov 09, 2018

SELL
$88.91 - $98.84 $16,981 - $18,878
-191 Reduced 1.19%
15,913 $1.51 Million
Q2 2018

Aug 06, 2018

BUY
$89.78 - $106.23 $121,651 - $143,941
1,355 Added 9.19%
16,104 $1.49 Million
Q1 2018

May 07, 2018

SELL
$92.01 - $123.21 $32,663 - $43,739
-355 Reduced 2.35%
14,749 $1.4 Million
Q4 2017

Jan 26, 2018

BUY
$89.56 - $98.21 $12,538 - $13,749
140 Added 0.94%
15,104 $1.46 Million
Q3 2017

Oct 11, 2017

BUY
$69.85 - $89.22 $1.05 Million - $1.34 Million
14,964
14,964 $1.33 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $293B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Blue Fin Capital, Inc. Portfolio

Follow Blue Fin Capital, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blue Fin Capital, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Blue Fin Capital, Inc. with notifications on news.